Category: General

Revenue up 40% and a $7.7B backlog. The real debate is the valuation.

A 20% crash in a month just created the sector’s most interesting entry debate in years.

480K deliveries already beat the Street. Now margins and Cybercab have to do the work.

Mounjaro sales up 125% in Q1. A new pill just launched. Q2 earnings could reset the story again.

Revenue grew 49% last quarter. The market punished it anyway.

A pre-earnings briefing just rewrote the investment case for China’s most beaten-down mega-cap.

A 45% year-to-date gain and a $56 billion capex cycle have the market asking the wrong question.

The gap between Wall Street’s boldest Fed call and actual market pricing is the trade of the second half.

Record revenue, 85% growth, and a raised outlook — yet the stock keeps sliding.

The Fed stress test cleared all 32 banks. The dividend and buyback wave starts now.